All News about Gilead Sciences
![](https://investorplace.com/wp-content/uploads/2022/10/stocks-to-buy-greedy1600-1024x576.png)
![](https://cdn.benzinga.com/files/images/story/2024/bz-pharma-briefs_3.jpeg?width=1200&height=800&fit=crop)
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
![](https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715.png)
![](https://www.marketbeat.com/logos/articles/med_20240212110357_gene-therapy-why-does-it-cost-millions-for-a-singl.jpg)
![](https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp)
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop)
$1000 Invested In This Stock 20 Years Ago Would Be Worth $10,000 Today
February 07, 2024
Via Benzinga
![](https://www.marketbeat.com/logos/articles/med_20240214075553_analysts-see-over-50-gains-in-these-2-mid-cap-biot.jpg)
Analysts see over 50% gains in these 2 mid-cap biotech stocks
February 14, 2024
Via MarketBeat
Topics
Artificial Intelligence
![](https://cdn.benzinga.com/files/images/story/2024/02/14/image39.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2024/GILD-Logo.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2024/02/12/image39.jpeg?width=1200&height=800&fit=crop)
Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B
February 12, 2024
Via Benzinga
Topics
Stocks
Exposures
US Equities
![](https://ml.globenewswire.com/media/aeea7200-7231-49dd-b4ba-ec680464b28c/small/brodsky-smith-logo-png-png.png)
From Brodsky & Smith LLC
Via GlobeNewswire
![](https://investorplace.com/wp-content/uploads/2020/10/gild-stock-4.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.png?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2024/CBAY.png?width=1200&height=800&fit=crop)
Drugmaker Gilead Sciences Scoops Up Liver-Disease Focused CymaBay Therapeutics For $4.3B
February 12, 2024
Via Benzinga
Exposures
Product Safety
![](https://www.investors.com/wp-content/uploads/2021/03/Stock-gilead-07a-adobe.jpg)
![](https://mms.businesswire.com/media/20240211034242/en/2030601/5/Logo_CymaBay-Therapeutics-Oct18-rgb-color.jpg)
Via Business Wire
![](https://img.freepik.com/free-photo/biotechnology-specialist-laboratory-conducting-experiments_23-2150468696.jpg?size=626&ext=jpg&ga=GA1.2.1846020111.1674633469&semt=ais)
Gilead Sciences Stock Approaches Daily Buying Area
February 12, 2024
Via Talk Markets
Exposures
COVID-19
![](https://talkmarkets.com/user_content/ckimages/orig_46090766321_9ae7b253d1_c.jpg)
Gilead-Backed Kyverna Overshoots Raised IPO Expectations
February 11, 2024
Via Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
![](https://mms.businesswire.com/media/20240208075998/en/778437/5/GCP_Primarylarge_1.jpg)
Via Business Wire
![](https://cdn.benzinga.com/files/images/story/2024/02/09/image_7.jpg?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2024/01/Stock-colorfullightbulb-generatedai-01-adobe.jpg)
![](https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600.png)
![](https://g.foolcdn.com/editorial/images/764423/drug-development-pharmaceutical-pharma-research-researchers-doctors.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/Bull-and-bear-stock-market-index_6.jpeg?width=1200&height=800&fit=crop)
S&P 500 Flirts With 5,000 As Magnificent 7 Tops $13 Trillion, NYCB Sinks: What's Driving Markets Wednesday?
February 07, 2024
Via Benzinga
Topics
Stocks
Exposures
US Equities
![](https://g.foolcdn.com/editorial/images/763810/physician-giving-medicine-to-elderly-patient.jpg)
Late-Session Earnings Bonanza: Ford, Chipotle, Snap & More
February 06, 2024
Via Talk Markets
Topics
Stocks
Exposures
US Equities
![](https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg)
Gilead Sciences (GILD) Q4 2023 Earnings Call Transcript
February 06, 2024
Via The Motley Fool
Topics
Earnings
Exposures
Financial
![](https://cdn.benzinga.com/files/images/story/2024/GileadSciences-Shutterstock.jpeg?width=1200&height=800&fit=crop)
![](https://mms.businesswire.com/media/20240206319017/en/778437/5/GCP_Primarylarge_1.jpg)
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.